Federal Circuit Upholds Acadia Pharmaceuticals’ Parkinson’s Drug Patent as Generics Firm Weighs Appeal

The Federal Circuit upheld the validity of an Acadia Pharmaceuticals patent related to a Parkinson’s disease drug. The ruling was influenced by double-patenting precedent established by the court last year. However, MSN Laboratories, a generics manufacturer, indicated it may pursue an en banc review of the decision. For a more detailed examination, visit the full article on Law360.